Efficacy

Megace ES is an effective treatment for your AIDS patients experiencing anorexia, cachexia, or an unexplained, significant weight loss.1 Help your patients gain weight and enhance their sense of well-being.1

Weight Gain Evaluated in the Pilot Study18

The weight gain associated with Megace ES and Megace®* was evaluated in patients with HIV-associated unintended weight loss.

Patients in the Megace ES Arm Gained an Average of 10% of Their Baseline Weight Over 12 Weeks (11.9 lbs) [Footnote: 16]

• This trial was conducted as a pilot study using a concentrated suspension of 575 mg/5mL megestrol acetate. Megace ES is available as megestrol acetate 125 mg per mL oral suspension. The initial recommended dose of Megace ES is 625 mg/5 mL

• Randomized, open-label, multicenter pilot study that enrolled 63 AIDS patients. Patients received either Megace ES (575 mg/5 mL) or Megace (800 mg/20 mL) once daily in the morning for 12 weeks

• Those patients receiving megestrol acetate oral suspension 800 mg/20 mL gained an average of 6% of their baseline weight over 12 weeks (7.7lbs)18

• Safety was similar for each arm of the trial

 

*Megestrol acetate oral suspension.

 

Go to References Go to References